Products Administration and submitted to the Japanese Ministry of Health, Labour and Welfare. According to InvestingPro analysis, GSK maintains a "GREAT" financial health score, positioning it ...

So, one of the milestones that I want to note right at the beginning of the article is that GSK announced that on January 28, 2025, regulatory authorities in China, Japan, and Europe accepted ...

British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale ...

Regulators in the EU, China, and Japan have started reviews of GSK's depemokimab, aiming to become the first drug for severe asthma that can be given just twice a year. The EMA and counterparts in ...

The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal infection for use in people aged 10 through 25 years, the company said on ...